Literature DB >> 1818055

Measurement of epidoxorubicin and its metabolites by high-performance liquid chromatography using an advanced automated sample processor.

N A Dobbs1, C J Twelves.   

Abstract

A sensitive and rapid method for measuring epidoxorubicin and its six metabolites by high-performance liquid chromatography using an advanced automated sample processor is described. Plasma samples (1 ml) were extracted using C2 cassettes, and reversed-phase chromatography was performed with an Apex II ODS column. The isocratic mobile phase of acetonitrile-0.019 M NaH2PO4 (pH 4.0) had a flow-rate of 1 ml/min and the fluorescence detector an excitation wavelength of 480 nm with an emission at 580 nm. Linear calibration curves were obtained which were reproducible both within-day and day-to-day (coefficients of variation less than 10%). The extraction efficacy of epidoxorubicin was 88% and ranged from 51 to 88% for the metabolites. This method has been successfully applied to measure the plasma levels of these compounds in patients receiving epidoxorubicin over a wide dose range (12-120 mg/m2) and in patients with disturbed liver biochemistry.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1818055     DOI: 10.1016/0378-4347(91)80485-u

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

1.  Maximum a posteriori Bayesian estimation of epirubicin clearance by limited sampling.

Authors:  Lorraine D Ralph; Alison H Thomson; Nicola A Dobbs; Chris Twelves
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

2.  Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity.

Authors:  N A Dobbs; C J Twelves; P Rizzi; J D Warwick; E M Metivier; R Williams; P J Johnson
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.

Authors:  C J Twelves; N A Dobbs; Y Michael; L A Summers; W Gregory; P G Harper; R D Rubens; M A Richards
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.